Hubble Therapeutics is a patient-focused biotechnology company developing research from Professor Bikash Pattnaik's lab at the University of Wisconsin-Madison. Hubble's primary focus is on developing novel gene therapy for Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two debilitating retinal diseases that lead to severe vision loss in adult and pediatric patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/25 | $7,300,000 | Series A |
WARF Ventures | undisclosed |
